Logo image of AMPH

AMPHASTAR PHARMACEUTICALS IN (AMPH) Stock Fundamental Analysis

NASDAQ:AMPH - Nasdaq - US03209R1032 - Common Stock - Currency: USD

23.58  +0.24 (+1.03%)

After market: 23.58 0 (0%)

Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to AMPH. AMPH was compared to 195 industry peers in the Pharmaceuticals industry. While AMPH belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on AMPH. This makes AMPH very considerable for value investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

AMPH had positive earnings in the past year.
In the past year AMPH had a positive cash flow from operations.
Each year in the past 5 years AMPH has been profitable.
AMPH had a positive operating cash flow in each of the past 5 years.
AMPH Yearly Net Income VS EBIT VS OCF VS FCFAMPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

1.2 Ratios

With an excellent Return On Assets value of 8.71%, AMPH belongs to the best of the industry, outperforming 92.31% of the companies in the same industry.
AMPH has a Return On Equity of 18.85%. This is amongst the best in the industry. AMPH outperforms 91.79% of its industry peers.
AMPH has a better Return On Invested Capital (11.31%) than 89.74% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AMPH is in line with the industry average of 14.87%.
Industry RankSector Rank
ROA 8.71%
ROE 18.85%
ROIC 11.31%
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
AMPH Yearly ROA, ROE, ROICAMPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15 20

1.3 Margins

The Profit Margin of AMPH (19.38%) is better than 92.82% of its industry peers.
AMPH's Profit Margin has improved in the last couple of years.
AMPH has a better Operating Margin (26.65%) than 92.31% of its industry peers.
In the last couple of years the Operating Margin of AMPH has grown nicely.
The Gross Margin of AMPH (50.50%) is better than 64.10% of its industry peers.
AMPH's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 26.65%
PM (TTM) 19.38%
GM 50.5%
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
AMPH Yearly Profit, Operating, Gross MarginsAMPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40 50

More info and screens

6

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMPH is creating some value.
The number of shares outstanding for AMPH has been reduced compared to 1 year ago.
AMPH has more shares outstanding than it did 5 years ago.
AMPH has a better debt/assets ratio than last year.
AMPH Yearly Shares OutstandingAMPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AMPH Yearly Total Debt VS Total AssetsAMPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

AMPH has an Altman-Z score of 2.40. This is not the best score and indicates that AMPH is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.40, AMPH is in the better half of the industry, outperforming 70.77% of the companies in the same industry.
AMPH has a debt to FCF ratio of 4.02. This is a neutral value as AMPH would need 4.02 years to pay back of all of its debts.
AMPH's Debt to FCF ratio of 4.02 is amongst the best of the industry. AMPH outperforms 87.18% of its industry peers.
AMPH has a Debt/Equity ratio of 0.80. This is a neutral value indicating AMPH is somewhat dependend on debt financing.
The Debt to Equity ratio of AMPH (0.80) is worse than 68.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF 4.02
Altman-Z 2.4
ROIC/WACC1.23
WACC9.22%
AMPH Yearly LT Debt VS Equity VS FCFAMPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

AMPH has a Current Ratio of 2.95. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
AMPH's Current ratio of 2.95 is in line compared to the rest of the industry. AMPH outperforms 51.79% of its industry peers.
A Quick Ratio of 2.02 indicates that AMPH has no problem at all paying its short term obligations.
AMPH has a Quick ratio (2.02) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.95
Quick Ratio 2.02
AMPH Yearly Current Assets VS Current LiabilitesAMPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

AMPH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.30%.
Measured over the past years, AMPH shows a very strong growth in Earnings Per Share. The EPS has been growing by 61.62% on average per year.
AMPH shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.05%.
The Revenue has been growing by 17.82% on average over the past years. This is quite good.
EPS 1Y (TTM)-4.3%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-28.85%
Revenue 1Y (TTM)8.05%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%-0.76%

3.2 Future

The Earnings Per Share is expected to decrease by -0.72% on average over the next years.
The Revenue is expected to grow by 4.44% on average over the next years.
EPS Next Y-16.92%
EPS Next 2Y-2.84%
EPS Next 3Y0.42%
EPS Next 5Y-0.72%
Revenue Next Year-1.48%
Revenue Next 2Y1.8%
Revenue Next 3Y2.18%
Revenue Next 5Y4.44%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AMPH Yearly Revenue VS EstimatesAMPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
AMPH Yearly EPS VS EstimatesAMPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 2 3

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 6.62, the valuation of AMPH can be described as very cheap.
Compared to the rest of the industry, the Price/Earnings ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 94.87% of the companies listed in the same industry.
AMPH is valuated cheaply when we compare the Price/Earnings ratio to 27.28, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 6.47, which indicates a rather cheap valuation of AMPH.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 93.33% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.76, AMPH is valued rather cheaply.
Industry RankSector Rank
PE 6.62
Fwd PE 6.47
AMPH Price Earnings VS Forward Price EarningsAMPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 94.87% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, AMPH is valued cheaper than 94.36% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.4
EV/EBITDA 5.63
AMPH Per share dataAMPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The excellent profitability rating of AMPH may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.11
EPS Next 2Y-2.84%
EPS Next 3Y0.42%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AMPH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (7/2/2025, 8:15:52 PM)

After market: 23.58 0 (0%)

23.58

+0.24 (+1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners72.67%
Inst Owner Change-5.17%
Ins Owners8.72%
Ins Owner Change6.64%
Market Cap1.11B
Analysts76.67
Price Target33.66 (42.75%)
Short Float %11.27%
Short Ratio7.85
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.55%
Min EPS beat(2)-4.55%
Max EPS beat(2)5.65%
EPS beat(4)2
Avg EPS beat(4)3.88%
Min EPS beat(4)-4.74%
Max EPS beat(4)19.17%
EPS beat(8)5
Avg EPS beat(8)11.41%
EPS beat(12)8
Avg EPS beat(12)16.64%
EPS beat(16)11
Avg EPS beat(16)20.36%
Revenue beat(2)0
Avg Revenue beat(2)-2.65%
Min Revenue beat(2)-2.87%
Max Revenue beat(2)-2.43%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-3.71%
Max Revenue beat(4)4.61%
Revenue beat(8)3
Avg Revenue beat(8)-0.34%
Revenue beat(12)6
Avg Revenue beat(12)-0.04%
Revenue beat(16)9
Avg Revenue beat(16)0.9%
PT rev (1m)-6.38%
PT rev (3m)-14.29%
EPS NQ rev (1m)1.36%
EPS NQ rev (3m)4.86%
EPS NY rev (1m)-0.3%
EPS NY rev (3m)0.82%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.43%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)-1.89%
Valuation
Industry RankSector Rank
PE 6.62
Fwd PE 6.47
P/S 1.52
P/FCF 7.4
P/OCF 5.75
P/B 1.48
P/tB 6.67
EV/EBITDA 5.63
EPS(TTM)3.56
EY15.1%
EPS(NY)3.64
Fwd EY15.45%
FCF(TTM)3.19
FCFY13.51%
OCF(TTM)4.1
OCFY17.38%
SpS15.5
BVpS15.94
TBVpS3.54
PEG (NY)N/A
PEG (5Y)0.11
Profitability
Industry RankSector Rank
ROA 8.71%
ROE 18.85%
ROCE 13.64%
ROIC 11.31%
ROICexc 13.56%
ROICexgc 26.64%
OM 26.65%
PM (TTM) 19.38%
GM 50.5%
FCFM 20.56%
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexcg growth 3Y24.9%
ROICexcg growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score7
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.8
Debt/FCF 4.02
Debt/EBITDA 2.39
Cap/Depr 73.47%
Cap/Sales 5.88%
Interest Coverage 7.56
Cash Conversion 76.31%
Profit Quality 106.07%
Current Ratio 2.95
Quick Ratio 2.02
Altman-Z 2.4
F-Score7
WACC9.22%
ROIC/WACC1.23
Cap/Depr(3y)86.1%
Cap/Depr(5y)106.5%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-4.3%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-28.85%
EPS Next Y-16.92%
EPS Next 2Y-2.84%
EPS Next 3Y0.42%
EPS Next 5Y-0.72%
Revenue 1Y (TTM)8.05%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%-0.76%
Revenue Next Year-1.48%
Revenue Next 2Y1.8%
Revenue Next 3Y2.18%
Revenue Next 5Y4.44%
EBIT growth 1Y-7.98%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year-5.73%
EBIT Next 3Y3.45%
EBIT Next 5Y5.95%
FCF growth 1Y192.27%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y145.14%
OCF growth 3Y29.62%
OCF growth 5Y38.57%